HIGHLIGHTS
- who: Yan Liang from the University of Bern, Switzerland have published the article: The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency, in the Journal: (JOURNAL)
- what: The aim of this study was to develop a pharmacokinetic/ pharmacodynamic model to predict YPEG-rhGH exposure and insulin-like growth factor-I (IGF-I) response and investigate the short-term clinical outcomes in children with GHD. The trial was doubleblind with regard to YPEG-rhGH dose, and the clinical assessments were . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.